書報討論

報告日期	報告題目	報告人
2024-03-22	Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma	蔡筱筠
2024-03-22	Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial	郭玟伶
2024-03-15	Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway	邱偉華
2024-03-15	Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies	劉玟均
2024-03-08	CRISPR-cas9 engineering of the RAG2 locus via complete coding sequence replacement for therapeutic applications	洪永豪

報告日期	報告題目	報告人
2024-03-22	Liquid biopsy epigenomic profiling for cancer subtyping	王祥宇
2024-03-22	Combination of DNA methylation biomarkers with multiparametric magnetic resonance and ultrasound imaging fusion biopsy to detect the local spread of prostate cancer	張恩承
2024-03-15	On the genetic basis of tail-loss evolution in humans and apes	李峻愷
2024-03-08	Tumor cell-intrinsic p38 MAPK signaling promotes IL1⍺-mediated stromal inflammation and therapeutic resistance in pancreatic cancer	陳玉蕙
2024-03-08	BCRP drives intrinsic chemoresistance in chemotherapy-naive breast cancer brain metastasis	黃珮甄

報告日期	報告題目	報告人
2024-03-22	Engineered bacterial outer membrane vesicles encapsulat-ing oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy	簡奕昇
2024-03-22	Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment	徐伯彦
2024-03-15	Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance	林宜蓁
2024-03-08	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial	宋富群